# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Non-Hodgkin lymphoma, childhood

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 18 results.
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Aug 01, 2018
Disease(s): Non-Hodgkin Lymphoma
Intervention(s): Tisagenlecleucel
Locations: Childrens Hospital Los Angeles, Los Angeles, California, United States
Childrens Healthcare of Atlanta At Scottish Rite, Atlanta, Georgia, United States
Johns Hopkins Oncology Center ORA, Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center MSKCC (8), New York, New York, United States
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States
... and 16 other locations.
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Recruiting
Last Changed: Oct 18, 2019
First Received: Jul 07, 2017
Disease(s): Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma, Malignant Glioma, Recurrent Central Nervous System Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Central Nervous System Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
Intervention(s): Erdafitinib, Laboratory Biomarker Analysis, Pharmacological Study
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Cardon Children's Medical Center, Mesa, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
... and 102 other locations.
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Recruiting
Last Changed: Oct 18, 2019
First Received: Jul 28, 2017
Disease(s): Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma, Malignant Glioma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Central Nervous System Neoplasm, Refractory Childhood Malignant Germ Cell Tumor, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Wilms Tumor
Intervention(s): Olaparib
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Cardon Children's Medical Center, Mesa, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
... and 101 other locations.
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Recruiting
Last Changed: Oct 17, 2019
First Received: Jul 18, 2017
Disease(s): Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Intervention(s): Laboratory Biomarker Analysis, Vemurafenib
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Cardon Children's Medical Center, Mesa, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
... and 102 other locations.
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Recruiting
Last Changed: Oct 18, 2019
First Received: Jul 11, 2017
Disease(s): Advanced Malignant Solid Neoplasm, ALK Fusion Protein Expression, ALK Gene Mutation, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, ROS1 Fusion Positive, ROS1 Gene Mutation
Intervention(s): Ensartinib, Laboratory Biomarker Analysis, Pharmacological Study
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Cardon Children's Medical Center, Mesa, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
... and 101 other locations.
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Recruiting
Last Changed: Oct 17, 2019
First Received: Jul 11, 2017
Disease(s): Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Refractory Central Nervous System Neoplasm, Refractory Childhood Malignant Germ Cell Tumor, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Wilms Tumor
Intervention(s): Larotrectinib, Larotrectinib Sulfate
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Cardon Children's Medical Center, Mesa, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
... and 104 other locations.
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Status: Recruiting
Last Changed: Mar 13, 2019
First Received: Apr 30, 2013
Disease(s): Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma/Leukemia
Intervention(s): Clofarabine, Mitoxantrone
Locations: New York Medical College, Valhalla, New York, United States
Levine Children's Hospital, Charlotte, North Carolina, United States
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Status: Recruiting
Last Changed: May 13, 2019
First Received: Jun 07, 2012
Disease(s): Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Intervention(s): Temsirolimus, Etoposide, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
Locations: Childrens Hospital Los Angeles, Los Angeles, California, United States
Children's Hospital Orange County, Orange, California, United States
UCSF School of Medicine, San Francisco, California, United States
The Children's Hospital, University of Colorado, Aurora, Colorado, United States
Children's National Medical Center, Washington, District of Columbia, United States
... and 28 other locations.
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Status: Recruiting
Last Changed: Sep 05, 2019
First Received: Aug 02, 2019
Disease(s): Lymphoblastic Lymphoma, Childhood
Intervention(s): Cyclophosphamide, Cytarabine, Dexamethasone, Daunorubicin, Doxorubicin, Ifosfamide, 6-Mercaptopurine, Methotrexate, PEG asparaginase, Prednisone, Prednisolone, Thioguanine, Vincristine, Vindesine
Locations: Univ.Klinik für Kinder- und Jugendheilkunde Graz, Klin. Abteilung für pädiatrische Hämato-Onkologie, Graz, Austria
Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck, Universitätsklinik für Pädiatrie I, Innsbruck, Austria
Kepler Universitätsklinikum, Med Campus IV / Onkologie, Linz, Austria
LKH Salzburg, Universitätsklinik für Kinder- und Jugendheilkunde, Kinderonkologie, Salzburg, Austria
St. Anna Kinderspital, Wien, Austria
... and 217 other locations.
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL
Status: Recruiting
Last Changed: Jun 03, 2019
First Received: Jun 03, 2019
Disease(s): Lymphoma, Non-Hodgkin, Lymphoblastic Lymphoma, Childhood, PTEN Loss, NOTCH1 Gene Mutation, Pediatric Cancer
Locations: Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China